CN102772491A - Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition - Google Patents
Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition Download PDFInfo
- Publication number
- CN102772491A CN102772491A CN2012102939655A CN201210293965A CN102772491A CN 102772491 A CN102772491 A CN 102772491A CN 2012102939655 A CN2012102939655 A CN 2012102939655A CN 201210293965 A CN201210293965 A CN 201210293965A CN 102772491 A CN102772491 A CN 102772491A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating a lower extremity atherosclerotic disease (LEAD). The traditional Chinese medicine composition comprises 25-40 parts of radix astragali and 10-20 parts of mulberry, also can comprise 10-20 parts of radix salviae miltiorrhizae, 10-20 parts of Chinese angelica, 6-12 parts of earthworm and 5-8 parts of leech, and can further comprise 6-12 parts of rhizoma acori tatarinowii, 6-12 parts of rhizoma alismatis, 5-15 parts of tea tree root and 5-18 parts of radix achyranthis bidentatae in parts by weight. The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating the LEAD. The traditional Chinese medicine composition provided by the invention has the advantages that the medicine offers syndrome differentiation and treatment with the characteristics of traditional Chinese medicine according to the symptoms of the LEAD, and has the effects of activating blood, dredging collaterals and resolving phlegm while placing extra emphasis on replenishing qi and tonifying deficiency so as to fundamentally improve the constitution of a patient, cut the links of worsening the phlegm, deficiency and stasis under a mutual effect, reduce the danger of transferring vessel impediment to heart in terms of prevention and control and realize an obvious curative effect; and the composition does not have toxic and side effects, is easily accepted by the patient, is made from few raw materials, is low in cost, and adopts a simple preparation technology.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and application thereof of treating artery of lower extremity atherosclerotic disease, specifically, is to be the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
(Lower Extremity Atherosclerotic Disease LEAD) is meant atherosis stricture of artery even the obturation of causing of artery of lower extremity to artery of lower extremity atherosclerotic disease, makes the lower limb tissue disease of chronic or acute ischemia symptom occur.China's reported literature, Beijing more than 60 years old elderly population be 16.4%, the metabolism syndrome crowd is 22.5%, diabetic population is 19.4%, sickness rate ten/height.
In motherland's medical science successive dynasties medical book, do not have record about " lower extremities disease ".According to the clinical manifestation of LEAD, primary disease should belong to motherland's medical science " necrosis ", " BI-syndrome involved the blood vessels " category, broadly also belongs to " syndrome of blood stasis " category.Begin to have " BI-syndrome involved the blood vessels " speech in " holy agent is always recorded " book, it is said: " courageous and upright Wen Zexuan stream, it is then puckery with fixed attention to tremble with fear, coagulate puckery not all right, then fur wither worried, muscle numbness "." element is asked the numbness opinion " point out " numbness be arteries and veins then blood clotting and do not flow ".In " General Treatise on the Cause and Symptoms of Diseases " to being described as of limb ischemia disease " passages through which vital energy circulates is gone, and all arises from brothers, and asthenia is the vim and vigour damage that declines then, can not its extremity of temperature, so the extremity cold of the limbs also "." a Ling Shu Miraculous Pivot or Divine Axis carbuncle piece of writing " has detailed description to " necrosis ": " send out in toe, name is said thromb angintis and thromboarteriosclerosis.Its shape is red black, stubbornly refuses to control.Not red black, not dead.Do not wane, suddenly cut it, then not dead.”。
Most scholars thinks that the main diseases of primary disease blocks because of deficiency of spleen and stomach, the expectorant stasis of blood at present, and its pathogenesis character is deficiency in origin and excess in superficiality.Because " the kidney being the origin of congenital constitution " posted part by nephroyin and nephroyang, be the root of life, main store essential substances blood.Spleen is " the foundation of acquired constitution ", " source of generating QI and blood " " The spleen has the function to transport and transform nutrients ".LEAD is more common in the old people, " element asks ancient times innocent opinion ": " seven or eight, irritability declines, the tendon being unable to move, and exhaustion of kidney-essence with promoting reproductive function, oligospermia, kidney declines, physique and configuration of the body being very feeble and atrophied."; Jing-Yue Complete Works cloud: " blood person essence-QI from water and grain also come in a continuous stream, and realification is in spleen ".Old people's spleen is suffered from a deficiency of the kidney and is declined, and deficiency of the spleen causing weakness of QI then spleen fortune is strong, the dysfunction of the spleen and give birth to humidogene expectorant, and phlegm-damp is gone into arteries and veins, and retardance blood normally moves, and blood is capable unfavorable, then becomes blood stasis.The modern causes eating and drinking without temperance, surfeit delicious food because the dietary that dietary structure and operating pressure cause changes, and lacks physical work in addition, and the exhaustion due to sexual indulgence person that stays up late again then causes asthenia of both the spleen and kidney body constitution." General Treatise on the Cause and Symptoms of Diseases " said again: " all expectorant persons, this is jammed by blood vessels, drinking-water gathers and does not dissipate, and becomes expectorant also ", the phlegm-turbidity and blood stasis blood agglomeration gathers in channels, forms the qi-asthenia phlegm stasis of blood." Ling Shu Miraculous Pivot or Divine Axis disorder of defensive QI opinion " said: " people has fat, and cream is arranged, and meat is arranged ", and if fat is too much, then body has change, at least " body does not have the cream pool ".Cream fat and body fluid homology are the thick turbid persons of body fluid, and it can dissolve in the blood.If its Excessive Intake, utilize, excretory function is not normal, blood fat is raise send out to expectorant is turbid, stagnation of phlegm is in venation, and venation is obstructed and the stasis of blood stagnates in vascular, and phlegm and blood stasis is sent out and is primary disease.Modern Chinese medicine doctor family thinks that hyperlipemia and hypercoagulability belong to " the expectorant stasis of blood " category of the traditional Chinese medical science.Expectorant coagulates and blood stasis is that the Atheromatosis reason is crucial, and the essence of " stasis of blood " then is believed to comprise AP, thrombosis, high blood clotting and hyperlipemia etc. in interior pathological state.
It is less that being used to of having reported at present treated LEAD Chinese medicine composition evident in efficacy; Chinese patent document application number: 200410072690.8; The applying date: 2004-11-09 discloses a kind of treatment vasculitis, scleroderma and arteriosclerosis lower extremities vascular occlusion disease drug and preparation thereof, and it is to be raw material and according to every flavor Chinese medicine different qualities with Radix Salviae Miltiorrhizae, Caulis Spatholobi, Olibanum, Myrrha, Radix Curcumae; Pulverize separately becomes fine powder; After pretreatment such as water extraction, proportional mixing is processed dosage forms such as tablet, capsule again, and this Drug therapy periphery artery occlusion property curative effect of disease is remarkable.Chinese patent document application number CN 200910017097.6, the applying date: 2009-07-24 discloses a kind of atherosis Chinese medicine preparation of type 2 diabetes mellitus artery of lower extremity of treating; This Chinese medicine preparation is to be processed by the component of following weight portion: 10～15 parts of Cortex Cinnamomis, 40～60 parts of the Radixs Astragali, 10～20 parts of Ramulus Cinnamomi; 30～50 parts of Herba Epimedii, 30～50 parts of Ramulus Euonymis, 5～10 parts of Radix Notoginseng; 10～20 parts on Flos Carthami, 6～10 parts of Rhizoma Chuanxiongs, 10～15 parts of Rhizoma Coptidis; 10～20 parts of Radix Cyathulaes show that through efficacy experiment this Chinese medicine preparation has its intimal hyperplasia of improvement, reduce the effect of plaque thickness and stabilize plaque.The flavour of a drug number of above-mentioned two kinds of medicines is more, makes troubles for the preparation of medicine, has also increased the cost of medicine.Therefore, it is particularly important that development treatment LEAD effect significantly also possesses flavor number Chinese medicine composition few, that be prone to preparation, the low advantage of cost simultaneously.
Summary of the invention
The objective of the invention is provides a kind of Chinese medicine composition of treating artery of lower extremity atherosclerotic disease to deficiency of the prior art.
One purpose more of the present invention is that a kind of purposes of above-mentioned Chinese medicine composition is provided.
For realizing above-mentioned purpose, the technical scheme that the present invention takes is:
A kind of Chinese medicine composition of treating artery of lower extremity atherosclerotic disease, it comprises following bulk drugs: Radix Astragali 25-40 part, Fructus Mori 10-20 part.
Preferably, the described Radix Astragali is that 27-35 part, described Fructus Mori are 13-17 parts.
Preferably, the described Radix Astragali is that 30 parts, described Fructus Mori are 15 parts.
Described Chinese medicine composition also can further comprise following bulk drugs: Radix Salviae Miltiorrhizae 10-20 part, Radix Angelicae Sinensis 10-20 part, Pheretima 6-12 part, Hirudo 5-8 part.
Preferably, described Radix Salviae Miltiorrhizae is that 12-18 part, described Radix Angelicae Sinensis are that 12-18 part, described Pheretima are that 8-11 part, described Hirudo are 6-7 parts.
Preferably, described Radix Salviae Miltiorrhizae is that 15 parts, described Radix Angelicae Sinensis are that 15 parts, described Pheretima are that 9 parts, described Hirudo are 6 parts.
Described Chinese medicine composition also can further comprise following bulk drugs: described Rhizoma Acori Graminei is that 6-12 part, described Rhizoma Alismatis are that 6-12 part, described Radix Camelliae sinensis are 5-15 parts, and described Radix Achyranthis Bidentatae is 5-18 part.
Preferably, described Rhizoma Acori Graminei is that 9 parts, described Rhizoma Alismatis are that 9 parts, described Radix Camelliae sinensis are 10 parts, and described Radix Achyranthis Bidentatae is 12 parts.
The medicament of described Chinese medicine composition can be tablet, capsule, granule, oral liquid, mixture or syrup.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:
The application of as above arbitrary described Chinese medicine composition in preparation treatment artery of lower extremity atherosclerotic disease medicine.
The advantage of Chinese medicine composition of the present invention is:
1, give the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs of tcm characteristic according to the LEAD symptom, the promoting blood circulation to remove obstruction in the collateral expectorant stresses the QI invigorating tonify deficiency simultaneously, thereby solves following problem: improve patients ' life quality from General Symptoms; Fundamentally improve patient's body constitution; Suffer from the link that continues development each other from the phase that pathogenesis blocks expectorant, void, the stasis of blood, from preventing and treating the danger of reduction BI-syndrome involved the blood vessels telepathy, thereby be harmonious with differentiation of tcm and preventive treatment of disease; Go deep into that it is basic, curative effect is obvious;
2, process by pure Chinese medicine, have no side effect, be easy to accepted by the patient;
3, raw material components is few, and abundant raw materials is easy to get, low price, and preparation technology is simple, is fit to promote the use of.
The specific embodiment
Elaborate in the face of the specific embodiment provided by the invention down.
The preparation (one) of embodiment 1 Chinese medicine composition one of the present invention
25 parts of the Radixs Astragali, 20 parts of Fructus Mori, conventional method decocts.
The preparation (two) of embodiment 2 Chinese medicine compositions one of the present invention
40 parts of the Radixs Astragali, 10 parts of Fructus Mori, conventional method decocts.
The preparation (three) of embodiment 3 Chinese medicine compositions one of the present invention
25 parts of the Radixs Astragali, 10 parts of Fructus Mori, conventional method decocts.
The preparation (four) of embodiment 4 Chinese medicine compositions one of the present invention
40 parts of the Radixs Astragali, 20 parts of Fructus Mori, conventional method decocts.
The preparation (five) of embodiment 5 Chinese medicine compositions one of the present invention
27 parts of the Radixs Astragali, 17 parts of Fructus Mori, conventional method decocts.
The preparation (six) of embodiment 6 Chinese medicine compositions one of the present invention
35 parts of the Radixs Astragali, 13 parts of Fructus Mori, conventional method decocts.
The preparation (seven) of embodiment 7 Chinese medicine compositions one of the present invention
30 parts of the Radixs Astragali, 15 parts of Fructus Mori, conventional method decocts.
The preparation (one) of embodiment 8 Chinese medicine compositions two of the present invention
25 parts of the Radixs Astragali, 20 parts of Fructus Mori, 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 8 parts of Hirudos, conventional method decocts.
The preparation (two) of embodiment 9 Chinese medicine compositions two of the present invention
40 parts of the Radixs Astragali, 10 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Pheretimas, 5 parts of Hirudos, conventional method decocts.
The preparation (three) of embodiment 10 Chinese medicine compositions two of the present invention
25 parts of the Radixs Astragali, 10 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 20 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 5 parts of Hirudos, conventional method decocts.
The preparation (four) of embodiment 11 Chinese medicine compositions two of the present invention
40 parts of the Radixs Astragali, 10 parts of Fructus Mori, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Pheretimas, 5 parts of Hirudos, conventional method decocts.
The preparation (five) of embodiment 12 Chinese medicine compositions two of the present invention
40 parts of the Radixs Astragali, 20 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 18 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 5 parts of Hirudos, conventional method decocts.
The preparation (six) of embodiment 13 Chinese medicine compositions two of the present invention
27 parts of the Radixs Astragali, 17 parts of Fructus Mori, 12 parts of Radix Salviae Miltiorrhizaes, 18 parts of Radix Angelicae Sinensis, 11 parts of Pheretimas, 7 parts of Hirudos, conventional method decocts.
The preparation (seven) of embodiment 14 Chinese medicine compositions two of the present invention
35 parts of the Radixs Astragali, 13 parts of Fructus Mori, 18 parts of Radix Salviae Miltiorrhizaes, 12 parts of Radix Angelicae Sinensis, 8 parts of Pheretimas, 6 parts of Hirudos, conventional method decocts.
The preparation (eight) of embodiment 15 Chinese medicine compositions two of the present invention
25 parts of the Radixs Astragali, 17 parts of Fructus Mori, 12 parts of Radix Salviae Miltiorrhizaes, 20 parts of Radix Angelicae Sinensis, 8 parts of Pheretimas, 7 parts of Hirudos, conventional method decocts.
The preparation (nine) of embodiment 16 Chinese medicine compositions two of the present invention
25 parts of the Radixs Astragali, 13 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 8 parts of Hirudos, conventional method decocts.
The preparation (ten) of embodiment 17 Chinese medicine compositions two of the present invention
30 parts of the Radixs Astragali, 15 parts of Fructus Mori, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Angelicae Sinensis, 9 parts of Pheretimas, 6 parts of Hirudos, conventional method decocts.
The preparation (one) of embodiment 18 Chinese medicine compositions three of the present invention
25 parts of the Radixs Astragali, 20 parts of Fructus Mori, 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 8 parts of Hirudos, 6 parts of Rhizoma Acori Graminei, 12 parts of Rhizoma Alismatis, 5 parts of Radix Camelliae sinensiss, 18 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (two) of embodiment 19 Chinese medicine compositions three of the present invention
40 parts of the Radixs Astragali, 10 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Pheretimas, 5 parts of Hirudos, 12 parts of Rhizoma Acori Graminei, 6 parts of Rhizoma Alismatis, 15 parts of Radix Camelliae sinensiss, 5 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (three) of embodiment 20 Chinese medicine compositions three of the present invention
25 parts of the Radixs Astragali, 10 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 20 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 5 parts of Hirudos, 12 parts of Rhizoma Acori Graminei, 12 parts of Rhizoma Alismatis, 5 parts of Radix Camelliae sinensiss, 5 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (four) of embodiment 21 Chinese medicine compositions three of the present invention
40 parts of the Radixs Astragali, 10 parts of Fructus Mori, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Pheretimas, 5 parts of Hirudos, 12 parts of Rhizoma Acori Graminei, 6 parts of Rhizoma Alismatis, 5 parts of Radix Camelliae sinensiss, 18 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (five) of embodiment 22 Chinese medicine compositions three of the present invention
40 parts of the Radixs Astragali, 20 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 18 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 5 parts of Hirudos, 12 parts of Rhizoma Acori Graminei, 12 parts of Rhizoma Alismatis, 15 parts of Radix Camelliae sinensiss, 5 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (six) of embodiment 23 Chinese medicine compositions three of the present invention
27 parts of the Radixs Astragali, 17 parts of Fructus Mori, 12 parts of Radix Salviae Miltiorrhizaes, 18 parts of Radix Angelicae Sinensis, 11 parts of Pheretimas, 7 parts of Hirudos, 6 parts of Rhizoma Acori Graminei, 12 parts of Rhizoma Alismatis, 5 parts of Radix Camelliae sinensiss, 5 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (seven) of embodiment 24 Chinese medicine compositions three of the present invention
35 parts of the Radixs Astragali, 13 parts of Fructus Mori, 18 parts of Radix Salviae Miltiorrhizaes, 12 parts of Radix Angelicae Sinensis, 8 parts of Pheretimas, 6 parts of Hirudos, 12 parts of Rhizoma Acori Graminei, 9 parts of Rhizoma Alismatis, 10 parts of Radix Camelliae sinensiss, 18 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (eight) of embodiment 25 Chinese medicine compositions three of the present invention
25 parts of the Radixs Astragali, 17 parts of Fructus Mori, 12 parts of Radix Salviae Miltiorrhizaes, 20 parts of Radix Angelicae Sinensis, 8 parts of Pheretimas, 7 parts of Hirudos, 12 parts of Rhizoma Acori Graminei, 12 parts of Rhizoma Alismatis, 15 parts of Radix Camelliae sinensiss, 18 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (nine) of embodiment 26 Chinese medicine compositions three of the present invention
25 parts of the Radixs Astragali, 13 parts of Fructus Mori, 20 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 6 parts of Pheretimas, 8 parts of Hirudos, 6 parts of Rhizoma Acori Graminei, 12 parts of Rhizoma Alismatis, 5 parts of Radix Camelliae sinensiss, 18 parts of Radix Achyranthis Bidentataes, conventional method decocts.
The preparation (ten) of embodiment 27 Chinese medicine compositions three of the present invention
30 parts of the Radixs Astragali, 15 parts of Fructus Mori, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Angelicae Sinensis, 9 parts of Pheretimas, 6 parts of Hirudos, 9 parts of Rhizoma Acori Graminei, 9 parts of Rhizoma Alismatis, 10 parts of Radix Camelliae sinensiss, 12 parts of Radix Achyranthis Bidentataes, conventional method decocts.
Need to prove that it is the conventional manufacture method of Chinese medicine decoction that the described conventional method of embodiment 1-27 decocts, and is about to described crude drug decocte with water and becomes decoction.
Embodiment 28 treatmentsLEAD
Medicinal tablet/capsular preparation
Get the arbitrary described medicine of embodiment 1-27, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice; Merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs deposition and spends the night; Get supernatant, be concentrated into thick extractum; Add pharmaceutic adjuvant (method according to routine is selected pharmaceutic adjuvant for use), vacuum drying is pulverized and is granulated, and is pressed into tablet or fills encapsulated.
Embodiment 29 treatmentsLEAD
The preparation of drug particles
Get the arbitrary described medicine of embodiment 1-27, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice; Merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs deposition and spends the night; Get supernatant, be concentrated into thick extractum; Add pharmaceutic adjuvant (method according to routine is selected pharmaceutic adjuvant for use), vacuum drying is pulverized and is granulated, drying, and granulate gets the 20g granule, packing 10g/ bag.
Embodiment 30 treatmentsLEAD
The preparation of drug mixture/oral liquid/syrup
Get the arbitrary described medicine of embodiment 1-27, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice; Merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs deposition and spends the night; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids (method according to routine is selected pharmaceutic adjuvant for use), process mixture, oral liquid or syrup.
Embodiment 31 treatments of the present inventionLEAD
The clinical trial of Chinese medicine composition
One, object of study
1. case is originated
2010-2012 old section wards of attached Yueyang hospitals of traditional Chinese and western medicine of Shanghai City university of TCM are collected in this research and the old LEAD deficiency of vital energy of outpatient service IIa phase is held expectorant blood stasis syndrome patient under the arm.
2. sample content
The N=120 example.Set α=0.01, β=0.2, power=0.80, δ=2 (μ
α+ μ
β) σ/√ N.
3. include standard in
By American Heart Association (AHA) peripheral blood vessel practice guidelines in 1993, ABI≤0.90, the probability person of obstruction of artery is arranged; Meeting artery of lower extremity atheromatosis Fontaine method clinical stages simultaneously belongs to IIa phase person (Fontaine method clinical stages--the I phase: asymptomatic, but can be with lower limb function complete or descend; The IIa phase: the slight limping; The IIb phase: in walk lamely to severe; The III phase: ischemic rest pain; The IV phase: ulcer or gangrene.) can be diagnosed as the artery of lower extremity atheromatosis selected.Selected back is according to syndrome of deficiency of QI and syndrome of intermin-gled phlegm and blood stasis standard in " State Standard of the People's Republic of China's tcm clinical practice diagnosis and treatment term syndrome part " (GB/T16751.2-1997) of State Bureau of Technical Supervision's issue; In conjunction with the related content of " lower Extremity Arterial Diseases diagnosis and treatment principle " in second whole nation old peripheral arteriosclerosis property disease symposium in 2008, the genus deficiency of vital energy is held expectorant blood stasis syndrome person under the arm and is finally included object of study in.Final selected patient intends 120 examples, is divided into four groups of treatment group one, treatment group two, treatment group three and matched groups at random, four groups of patient age 60-80 year, male or female, and complication, age ratio have comparability than the difference not statistically significant.
4. exclusion standard
(1) getting rid of the sick Fontaine method of subordinate's main drive pulse atherosclerosis clinical stages belongs to other the clinical stages persons beyond the IIa phase; Get rid of other ischemic disease of limb such as thromboangiitis obliterans, Takayasu arteritis, raynaud disease, cold injured blood vessel disease;
(2) all patients all get rid of actute infection, tumor, severe cardiac hepatic and kidney function obstacle, operation or wound, connective tissue disease etc. influence the other diseases of immune factor level in the recent period.Except gestation, women breast-feeding their children, to this test Chinese medicine composition or Western medicine allergy sufferers, stupor, brain function serious hindrance person.The hyperlipidemia patient that causes owing to medicine (like phenothiazines, adrenocortical steroid and some contraceptive etc.); Hyperthyroidism person; Using heparin, thyroxine therapy and other patient who influences the blood lipid metabolism medicine or use immunosuppressant, reinforcing agent.
5. randoming scheme is divided into groups
Produce 120 random digits with computer earlier, be divided into treatment group one, treatment group two, treatment group three and matched group, then the result is put into the preprepared envelope according to random method.The person of including in is numbered according to time sequencing, extract envelope then and divide into groups.
Two, research method
1. AAi detects
No smoking, drink, have tea or coffee for 6h before the experimenter measured.The inactive vasodilation of 24h before the inspection.Patient's dorsal position is loosened the 5min at least that has a rest, and standard desktop mercurial sphygmomanometer cuff is tied up in upper arm and lower limb ankle.Brachial artery is aimed at upper arm cuff air bag sign place, and the cuff lower edge is apart from fossa cubitalis band 2～3cm, and the cuff elasticity is advisable with the lucky finger of putting into; Lower limb cuff air bag sign place is positioned at preaxial, and the cuff lower edge is apart from internal malleolus 1～2cm, and the cuff elasticity is the same.Stethoscope places brachial artery, the dorsal artery of foot place of beating.Ankle blood pressure, arm pressure value are respectively surveyed 3 times, average as ankle blood pressure, arm pressure value.The order of measuring is pressed with certain influence to bilateral ankle tremulous pulse; Generally brachial artery begins from the right side; Be the systolic pressure of right side dorsal artery of foot, right side posterior tibial artery, left side dorsal artery of foot, left side posterior tibial artery, left side brachial artery lower limb ankle tremulous pulse and the ratio of homonymy brachial artery systolic pressure successively; Amount of calculation records ABI, gets low value analysis.Give respectively when object of study is included when research and off-test administration in on-test and detecting.
2. administering mode
Treatment group one, two, three is taken the Chinese medicine composition of embodiment 7,17,27 respectively, this Chinese medicine composition decoct to concentration for containing crude drug amount 0.25g/mL, every day 2 times; Each 140ml is oral; Add usefulness: simvastatin (providing) by Mo Shadong company, every day 1 time, each 40mg is oral; Visit aspirin (Bayer A.G), every day 1 time, each 100mg is oral; Lisinopril (Five continents drugmaker provides), every day 1 time, each 10mg is oral.
Matched group is taken simvastatin (being provided by Mo Shadong company), and every day 1 time, each 40mg is oral; Visit aspirin (Bayer A.G provides), every day 1 time, each 100mg is oral; Lisinopril (Five continents drugmaker provides), every day 1 time, each 10mg is oral; Each organized administration 3 months.
3. tcm symptom scale assessment
According to syndrome of deficiency of QI and syndrome of intermin-gled phlegm and blood stasis standard in " State Standard of the People's Republic of China's tcm clinical practice diagnosis and treatment term syndrome part " (GB/T 16751.2-1997) of State Bureau of Technical Supervision's issue; Related content in conjunction with " lower Extremity Arterial Diseases diagnosis and treatment principle " in second whole nation old peripheral arteriosclerosis property disease symposium in 2008; Make this test tcm symptom assessment scale, see table 1.
Table 1 tcm symptom marking scales
Four groups of patient's on-tests and carry out the scoring of tcm symptom scale respectively when finishing, and carry out relatively reaching before and after self between group relatively.
Symptom classification and score, curative effect determinate standard (according to new Chinese medicine clinical research guideline) be as follows:
Symptom classification and score are: severe is 3 minutes, and moderate is 2 minutes, slightly is 1 minute, and asymptomatic is 0 minute;
Curative effect determinate standard: control: clinical symptoms, sign disappear or basic the disappearance, and the syndrome integration reduces >=95%; Produce effects: clinical symptoms, sign are obviously improved, and the syndrome integration reduces >=70%; Effectively: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces >=30%; Invalid: clinical symptoms, sign do not have obvious improvement, even increase the weight of, the syndrome integration reduces less than 30%.
4. in the femoral artery-middle film (IMT) detects
Before on-test, reach when finishing and detect with color Doppler echocardiography (ATL5000/VIVID7 type) frequency probe 7.5～13MHz.The person under inspection gets dorsal position, in demonstration femoral artery tube chamber and the front and rear wall-middle film, measure IMT, repeated measure 3 times is got its meansigma methods.Doppler sample volume is placed above 1.0cm place, femoral artery bifurcated plane.
5. serum detection method
(1) the ELLISA method detects IFN-γ, IL-4 and calculates its ratio.
(2) lipid determination (comprising triglyceride (Tc), cholesterol (TG), high density lipoprotein (HDL), low density lipoprotein, LDL (LDL)): the 7170s of Hitachi type, fully-automatic large-scale biochemistry analyzer.
Experiment is preceding, experiment finishes each and detects once.
6. statistical analysis
(t check, paired t-test are adopted in
± S) expression, measurement data to measurement data with mean ± standard deviation; Enumeration data adopts X 2 test; Ranked data adopt Ridit to analyze.Adopt SPSS 16.0 statistical software statistical analysiss.
Three, result
1. the tcm syndrome curative effect relatively
Each is organized the tcm syndrome efficacy result and sees table 2.Can know that by table 2 one 30 examples are organized in treatment, produce effects 7 examples; Effective 17 examples; Invalid 4 examples; Increase the weight of 2 examples; Total effective rate is 80%.2 30 examples are organized in treatment, produce effects 8 examples; Effective 16 examples; Invalid 4 examples; Increase the weight of 2 examples; Total effective rate is 80%.3 30 examples are organized in treatment, produce effects 8 examples; Effective 17 examples; Invalid 3 examples; Increase the weight of 2 examples; Total effective rate is 83.33%.Matched group 30 examples, produce effects 6 examples; Effective 14 examples; Invalid 6 examples; Increase the weight of 4 examples; Total effective rate is 66.7%.Treatment group one, two, three respectively with matched group relatively, all have significant difference (P < 0.05), show that treatment group one, two, three tcm syndrome curative effects all are superior to matched group.Treatment group one, two, compare in twos between three, difference is not remarkable.
Table 2 is respectively organized the tcm syndrome curative effect relatively
Annotate: compare with matched group,
▲P<0.05.
2. Smax (plaque area), IMT are relatively
Each is organized the testing result of Smax, IMT and sees table 3.Can know by table 3, the equal no difference of science of statistics of Smax before and after one, two, three treatments of treatment group (P>0.05), but downward trend is arranged.Compare significant difference is all arranged respectively with after the treatment of control group after treatment group one, two, three treatment (P 0.05).The equal no difference of science of statistics of IMT before and after one, two, three treatments of treatment group (P>0.05), but downward trend is arranged.Compare significant difference is all arranged respectively with after the treatment of control group after treatment group one, two, three treatment (P 0.05).
Smax, IMT compare (
± S) before and after each group treatment of table 3
Annotate: relatively preceding with treatment, ● P>0.05; Compare with matched group, ▲ P < 0.05.
3. IL-4, IFN-γ are relatively
IL-4, IFN-γ testing result are seen table 4.Can find out that from table 4 treatment group one, two, three treatment back serum IL-4 levels all obviously raise, IFN-γ level obviously lowers, relatively have before and after the treatment obvious significant difference (P 0.05, P 0.05); Treatment group one, two, three treatment back serum IL-4 levels all obviously raise, and IFN-γ level obviously lowers, relatively have before and after the treatment obvious significant difference (P 0.05, P 0.05); Treatment group one, two, three respectively with treatment of control group after compare each index all have obvious significant difference (P 0.05, P 0.05).
IL-4, IFN-γ compare (
± S) before and after each group treatment of table 4
Annotate: relatively preceding with treatment, * P＜0.05; Compare with matched group, ▲ P < 0.05.
4. blood fat (Tc, TG, HDL, LDL) relatively
Blood fat (Tc, TG, HDL, LDL) testing result is seen table 5.Can find out from table 5, Tc before and after treatment group one, two, three treatment, TG, HDL, the equal no difference of science of statistics of LDL (P>0.05, P 0.05, P 0.05, P 0.05); Treatment group one, two, three is treated back Tc, TG, HDL, LDL relatively with matched group respectively, all no difference of science of statistics (P>0.05, P 0.05, P 0.05, P 0.05).
Tc, TG, HDL, LDL compare (
± S) before and after each group treatment of table 5
Annotate: relatively preceding with treatment, ● P>0.05; Compare ▲ P with matched group>0.05.
Above statistical result shows, traditional Chinese medicine composition for treating LEAD of the present invention, and showing efficient through the tcm symptom scoring obviously increases, and Smax value, IMT value descend to some extent simultaneously, and IL-4, IFN-γ have obvious rising, show that it is evident in efficacy.Its reason is that mainly this Chinese medicine composition is is that spleen is suffered from a deficiency of the kidney and is this from LEAD, and the expectorant stasis of blood is started with for the pathology pathogenesis of the disease of mark, gives the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs of tcm characteristic according to the LEAD symptom, and the promoting blood circulation to remove obstruction in the collateral expectorant stresses the QI invigorating tonify deficiency simultaneously.In the crude drug of this Chinese medicine composition, the monarch drug Radix Astragali: Gan Wen is apt to into taste, is the invigorating the spleen and replenishing QI key medicine, can go into the lung replenishing and restoring lung-QI again, and the gas of spleen lung promotes the defeated cloth of body fluid, the unlikely formation expectorant stasis of blood, and the Radix Astragali also can qi-supplementing, blood-engendering, tonifying QI to promote blood circulation; The monarch drug Fructus Mori: sweet, sour, cold, return liver, kidney channel, the moon of ability liver and kidney tonifying is held concurrently and can be brought down a fever replenishing blood and nourishing liver by removing heat from blood; Minister is with Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Pheretima nourshing blood and promoting blood circulation, disperse blood stasis and dredge collateral; Radix Salviae Miltiorrhizae property bitter cold wherein, both removing heat from blood and promoting blood circulation, heat clearing away eliminating carbuncle again, the kind blood vessels that can pass through, stasis-dispelling and pain-killing share the common pyretic toxicity of dispeling, the merit of dredging blood vessels with the Radix Camelliae sinensis of kind promoting blood flow to regulate menstruation, heat-clearing and toxic substances removing; The sweet Wen Zhirun of Radix Angelicae Sinensis is longer than and enriches blood, and is the panacea of enriching blood, and Xin Hangwen is logical again, enriches blood and invigorates blood circulation, and dispersing cold for relieving pain is the key medicine of blood-activating and qi-promoting, the usefulness of the Radix Astragali, then enrich blood, circulation of qi promoting, the power of invigorating blood circulation be more special; Pheretima is salty, and is cold, and property is walked string, and the capable network of being good at stimulating the menstrual flow matches with the Radix Astragali, Radix Angelicae Sinensis, the effect of more beneficial promoting blood circulation to remove obstruction in the collateral, and other has the merit of diuresis, and turbid damp is gone from urine; Assistant is with Rhizoma Acori Graminei, Radix Camelliae sinensis, Rhizoma Alismatis dispelling dampness and promoting diuresis, heat-clearing and toxic substances removing; The hot temperature fragrance of Rhizoma Acori Graminei, kind turbid, the stomach of being amusing of removing dampness; Rhizoma Alismatis is sweet, and is cold, inducing diuresis to remove edema, eliminating dampness by diuresis, expels the heat-evil, and property is light oozes, and its diuretic effect is stronger, share Rhizoma Acori Graminei, Pheretima, Radix Camelliae sinensis, Radix Achyranthis Bidentatae, and then turbid damp goes to the greatest extent, and the usefulness of assistant Radix Salviae Miltiorrhizae, Radix Camelliae sinensis heat clearing away is arranged; Radix Achyranthis Bidentatae is to be messenger drug: promoting blood circulation to restore menstrual flow, invigorating the liver and kidney, bone and muscle strengthening, relieving stranguria by diuresis, ignite (blood) are descending, are to be the kidney channel guiding drug.All medicines are shared; Mend the effect that thin arteries and veins is invigorated blood circulation with playing training; Thereby improve patients ' life quality from General Symptoms, fundamentally improve patient's body constitution, block the phase of expectorant, void, the stasis of blood from pathogenesis and suffer from the link that continues development each other; From preventing and treating the danger that reduces the BI-syndrome involved the blood vessels telepathy, be harmonious with differentiation of tcm and preventive treatment of disease.
The above only is a preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; Can also make some improvement and replenish, these improvement and replenish and also should be regarded as protection scope of the present invention.
Claims (10)
1. a Chinese medicine composition of treating artery of lower extremity atherosclerotic disease is characterized in that, it comprises following bulk drugs: Radix Astragali 25-40 part, Fructus Mori 10-20 part.
2. Chinese medicine composition according to claim 1 is characterized in that, the described Radix Astragali is 27-35 part, and described Fructus Mori are 13-17 parts.
3. Chinese medicine composition according to claim 1 is characterized in that, the described Radix Astragali is 30 parts, and described Fructus Mori are 15 parts.
4. Chinese medicine composition according to claim 1 is characterized in that, it also comprises following bulk drugs: Radix Salviae Miltiorrhizae 10-20 part, Radix Angelicae Sinensis 10-20 part, Pheretima 6-12 part, Hirudo 5-8 part.
5. Chinese medicine composition according to claim 4 is characterized in that, described Radix Salviae Miltiorrhizae is that 12-18 part, described Radix Angelicae Sinensis are that 12-18 part, described Pheretima are that 8-11 part, described Hirudo are 6-7 parts.
6. Chinese medicine composition according to claim 5 is characterized in that, described Radix Salviae Miltiorrhizae is that 15 parts, described Radix Angelicae Sinensis are that 15 parts, described Pheretima are that 9 parts, described Hirudo are 6 parts.
7. according to the arbitrary described Chinese medicine composition of claim 4-6, it is characterized in that it also comprises following bulk drugs: Rhizoma Acori Graminei 6-12 part, Rhizoma Alismatis 6-12 part, Radix Camelliae sinensis 5-15 part, Radix Achyranthis Bidentatae 5-18 part.
8. Chinese medicine composition according to claim 7 is characterized in that, described Rhizoma Acori Graminei is that 9 parts, described Rhizoma Alismatis are that 9 parts, described Radix Camelliae sinensis are 10 parts, and described Radix Achyranthis Bidentatae is 12 parts.
9. according to the arbitrary described Chinese medicine composition of claim 1-6, it is characterized in that the medicament of described Chinese medicine composition is tablet, capsule, granule, oral liquid, mixture or syrup.
10. the application of the arbitrary described Chinese medicine composition of claim 1-6 in preparation treatment artery of lower extremity atherosclerotic disease medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210293965.5A CN102772491B (en) | 2012-08-17 | 2012-08-17 | Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210293965.5A CN102772491B (en) | 2012-08-17 | 2012-08-17 | Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102772491A true CN102772491A (en) | 2012-11-14 |
| CN102772491B CN102772491B (en) | 2014-03-26 |
Family
ID=47117748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210293965.5A Active CN102772491B (en) | 2012-08-17 | 2012-08-17 | Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772491B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288392A (en) * | 2014-11-07 | 2015-01-21 | 田丽华 | Traditional Chinese medicine for treating atherosclerosis |
| CN104435449A (en) * | 2014-12-23 | 2015-03-25 | 青岛市市立医院 | Pharmaceutical composition for resisting atherosclerosis and application of pharmaceutical composition |
| CN104645244A (en) * | 2015-03-14 | 2015-05-27 | 朱延朋 | Traditional Chinese medicine composition for treating atherosclerosis |
| CN114767801A (en) * | 2022-05-10 | 2022-07-22 | 北京中医药大学东方医院 | Traditional Chinese medicine composition for preventing and treating atherosclerosis cerebral infarction |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634353A (en) * | 2004-11-09 | 2005-07-06 | 天津同仁堂股份有限公司 | Medicine for treating vasculitis, scleriasis and arteriosclerosis type lower limb vascular occlusion |
| CN101041045A (en) * | 2007-04-19 | 2007-09-26 | 韩曙光 | Capsule for treating cardiac and cerebral vascular diseases and promoting blood circulation and its preparation process |
| CN102389470A (en) * | 2011-11-11 | 2012-03-28 | 吴淑玺 | Traditional Chinese medicinal composition for promoting blood circulation and removing obstructions in channels |
-
2012
- 2012-08-17 CN CN201210293965.5A patent/CN102772491B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634353A (en) * | 2004-11-09 | 2005-07-06 | 天津同仁堂股份有限公司 | Medicine for treating vasculitis, scleriasis and arteriosclerosis type lower limb vascular occlusion |
| CN101041045A (en) * | 2007-04-19 | 2007-09-26 | 韩曙光 | Capsule for treating cardiac and cerebral vascular diseases and promoting blood circulation and its preparation process |
| CN102389470A (en) * | 2011-11-11 | 2012-03-28 | 吴淑玺 | Traditional Chinese medicinal composition for promoting blood circulation and removing obstructions in channels |
Non-Patent Citations (2)
| Title |
|---|
| 王一: "《北京中医药大学 中医学专业硕士学位论文》", 6 July 2012 * |
| 骆丽娟: "益气补肾活血方治疗颈动脉粥样硬化的临床观察", 《辽宁中医杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288392A (en) * | 2014-11-07 | 2015-01-21 | 田丽华 | Traditional Chinese medicine for treating atherosclerosis |
| CN104435449A (en) * | 2014-12-23 | 2015-03-25 | 青岛市市立医院 | Pharmaceutical composition for resisting atherosclerosis and application of pharmaceutical composition |
| CN104435449B (en) * | 2014-12-23 | 2018-09-07 | 青岛市市立医院 | A kind of pharmaceutical composition of antiatherosclerosis and its application |
| CN104645244A (en) * | 2015-03-14 | 2015-05-27 | 朱延朋 | Traditional Chinese medicine composition for treating atherosclerosis |
| CN114767801A (en) * | 2022-05-10 | 2022-07-22 | 北京中医药大学东方医院 | Traditional Chinese medicine composition for preventing and treating atherosclerosis cerebral infarction |
| CN114767801B (en) * | 2022-05-10 | 2023-04-14 | 北京中医药大学东方医院 | Traditional Chinese medicine composition for preventing and treating atherosclerosis cerebral infarction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102772491B (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102847064A (en) | Chinese herbal medicine used for inhibition of malignant tumor metastasis | |
| CN108743892A (en) | The preparation method and applications of " Shengyang Yiwei Decoction " side's Chinese medical extract | |
| CN102772491B (en) | Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition | |
| CN102631647A (en) | Chinese patent medicine mixture for treating acute urticaria | |
| CN1977899B (en) | Medicine for treating rheumatoid arthritis | |
| CN109224039B (en) | Chinese medicinal composition for treating kidney fibrosis and tonifying kidney | |
| CN105999049A (en) | Traditional Chinese medicine composition for treating chronic renal failure and complications thereof | |
| CN110038066A (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic fatigue syndrome | |
| CN102512591A (en) | Composition with functions of losing weight and reducing blood glucose and lipid | |
| CN103157062A (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN102641424B (en) | Chinese prepared medicine mixture for treating acute urticaria | |
| CN102614344B (en) | Traditional Chinese medicine for treating qi-blood deficiency periodontitis, preparation method and administration method thereof | |
| CN101062340B (en) | Chinese traditional medicine composition for liver revovery | |
| CN113274439A (en) | Traditional Chinese medicine composition for treating liver diseases and application thereof | |
| CN104189649A (en) | Traditional Chinese medicine composition for treating recurrent genital herpes | |
| CN102641381A (en) | Chinese patent medicine for treating acute urticaria | |
| CN102631648A (en) | Chinese patent medicine for treating acute urticaria | |
| CN102631483A (en) | Traditional Chinese medicine (TCM) for treating acute urticaria | |
| CN110463799A (en) | A kind of wild plant composition of protect liver constipation-relieving tea | |
| CN102641422B (en) | Chinese patent medicine for treating acute urticaria | |
| CN113413445B (en) | Composition and preparation method and application thereof | |
| CN106109946A (en) | A kind of biological capsule treating Secondary Hyperlipidemia and preparation method | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105853582A (en) | Folium artemisiae argyi containing medicine preparation for treating cholelithiasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |